<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01118338</url>
  </required_header>
  <id_info>
    <org_study_id>648</org_study_id>
    <nct_id>NCT01118338</nct_id>
  </id_info>
  <brief_title>Evaluation of Two Different Designs of Bausch &amp; Lomb Contact Lenses</brief_title>
  <official_title>A Study to Evaluate the Product Performance of Two Different Designs of Bausch &amp; Lomb PureVisionÂ® Contact Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this one month study is to evaluate the product performance of a redesigned&#xD;
      PureVision Contact Lens compared to the PureVision Contact Lens when worn on a daily wear&#xD;
      basis by wearers of contact lenses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptoms and Complaints</measure>
    <time_frame>1 month</time_frame>
    <description>Symptoms/complaints were assessed on a scale from 0 to 100, with 0 denoting unfavorable symptoms/complaints and 100 denoting the most favorable rating. The generic scale was comprised of 14 separate questions, where each assessed the denoted symptom/complaint with a score between 0 and 100. The total score was not calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>1 month</time_frame>
    <description>Visual acuity was assessed by distance high contrast logarithm of the minimum angle of resolution (logMAR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Eyes With &gt; Grade 2 Slit Lamp Findings</measure>
    <time_frame>1 month</time_frame>
    <description>Graded slit lamp findings for each eye, including epithelial edema, epithelial microcysts, corneal staining, limbal and bulbar injections, upper lid tarsal conjunctival abnormalities, corneal neovascularization, and corneal infiltrates were graded for severity on a scale from 0 (No Finding) to 4 (Severe Finding). The outcome measure is any finding &gt; grade 2, across abnormalities.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">376</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>Redesigned Purevision Contact Lens</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Redesigned Bausch &amp; Lomb PureVision contact lens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PureVision Contact Lens</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bausch &amp; Lomb PureVision contact lens</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Redesigned Purevision Contact Lens</intervention_name>
    <description>Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.</description>
    <arm_group_label>Redesigned Purevision Contact Lens</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PureVision Contact Lens</intervention_name>
    <description>Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.</description>
    <arm_group_label>PureVision Contact Lens</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must have clear central corneas and be free of any anterior segment&#xD;
             disorders.&#xD;
&#xD;
          -  Subjects must be adapted wearers of one of the listed contact lenses&#xD;
&#xD;
          -  Subjects must be myopic&#xD;
&#xD;
          -  Subjects must use a lens care system on a regular basis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have worn gas permeable (GP) contact lenses within the last 30 days of&#xD;
             polymethylmethacrylate (PMMA) lenses within the last 3 months.&#xD;
&#xD;
          -  Subjects with any systemic disease affecting ocular health.&#xD;
&#xD;
          -  Subjects using any systemic or topical medications that will, in the Investigator's&#xD;
             opinion, affect ocular physiology or lens performance.&#xD;
&#xD;
          -  Subjects with an active ocular disease or are using any ocular medication.&#xD;
&#xD;
          -  Subjects with any &quot;Present&quot; finding during the slit lamp examination that, in the&#xD;
             Investigator's judgment, interferes with contact lens wear.&#xD;
&#xD;
          -  Subjects who have had any corneal surgery (eg, refractive surgery).&#xD;
&#xD;
          -  Subjects who have participated in any drug or device clinical investigation within two&#xD;
             weeks prior to entry into this study and/or during the period of study participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerard Cairns, MCOptom, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch &amp; Lomb</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 30, 2010</study_first_submitted>
  <study_first_submitted_qc>May 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2010</study_first_posted>
  <results_first_submitted>August 21, 2020</results_first_submitted>
  <results_first_submitted_qc>September 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 6, 2020</results_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>contact lens</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>There were 188 participants enrolled into each group, for a total of 376 participants enrolled. There were 185 participants in the redesigned group and 183 participants in the control group who were eligible and dispensed lenses.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Redesigned Purevision Contact Lens</title>
          <description>Redesigned Bausch &amp; Lomb PureVision contact lens&#xD;
Redesigned Purevision Contact Lens: Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.</description>
        </group>
        <group group_id="P2">
          <title>PureVision Contact Lens</title>
          <description>Bausch &amp; Lomb PureVision contact lens&#xD;
PureVision Contact Lens: Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="185"/>
                <participants group_id="P2" count="183"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="182"/>
                <participants group_id="P2" count="174"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Redesigned Purevision Contact Lens</title>
          <description>Redesigned Bausch &amp; Lomb PureVision contact lens&#xD;
Redesigned Purevision Contact Lens: Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.</description>
        </group>
        <group group_id="B2">
          <title>PureVision Contact Lens</title>
          <description>Bausch &amp; Lomb PureVision contact lens&#xD;
PureVision Contact Lens: Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="185"/>
            <count group_id="B2" value="183"/>
            <count group_id="B3" value="368"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.0" lower_limit="18" upper_limit="63"/>
                    <measurement group_id="B2" value="30.6" lower_limit="18" upper_limit="52"/>
                    <measurement group_id="B3" value="31.3" lower_limit="18" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="266"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Symptoms and Complaints</title>
        <description>Symptoms/complaints were assessed on a scale from 0 to 100, with 0 denoting unfavorable symptoms/complaints and 100 denoting the most favorable rating. The generic scale was comprised of 14 separate questions, where each assessed the denoted symptom/complaint with a score between 0 and 100. The total score was not calculated.</description>
        <time_frame>1 month</time_frame>
        <population>There were 185 participants (370 eyes) in the redesigned group and 183 participants (366 eyes) in the control group who were eligible and dispensed lenses. There were 368 dispensed eyes in the redesigned group and 360 dispensed eyes in the control group evaluable for the analysis population for the assessment of symptoms and complaints.</population>
        <group_list>
          <group group_id="O1">
            <title>Redesigned Purevision Contact Lens</title>
            <description>Redesigned Bausch &amp; Lomb PureVision contact lens&#xD;
Redesigned Purevision Contact Lens: Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.</description>
          </group>
          <group group_id="O2">
            <title>PureVision Contact Lens</title>
            <description>Bausch &amp; Lomb PureVision contact lens&#xD;
PureVision Contact Lens: Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.</description>
          </group>
        </group_list>
        <measure>
          <title>Symptoms and Complaints</title>
          <description>Symptoms/complaints were assessed on a scale from 0 to 100, with 0 denoting unfavorable symptoms/complaints and 100 denoting the most favorable rating. The generic scale was comprised of 14 separate questions, where each assessed the denoted symptom/complaint with a score between 0 and 100. The total score was not calculated.</description>
          <population>There were 185 participants (370 eyes) in the redesigned group and 183 participants (366 eyes) in the control group who were eligible and dispensed lenses. There were 368 dispensed eyes in the redesigned group and 360 dispensed eyes in the control group evaluable for the analysis population for the assessment of symptoms and complaints.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="360"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lens handling upon insertion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.2" spread="17.7"/>
                    <measurement group_id="O2" value="83.6" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Comfort upon insertion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.1" spread="21.7"/>
                    <measurement group_id="O2" value="74.6" spread="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burning/stinging upon insertion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.6" spread="19.0"/>
                    <measurement group_id="O2" value="83.2" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Comfort throughout the day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1" spread="22.2"/>
                    <measurement group_id="O2" value="73.0" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of day comfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.6" spread="24.8"/>
                    <measurement group_id="O2" value="65.1" spread="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lens awareness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.4" spread="22.6"/>
                    <measurement group_id="O2" value="72.1" spread="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lens cleanliness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.5" spread="16.5"/>
                    <measurement group_id="O2" value="81.5" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.6" spread="22.4"/>
                    <measurement group_id="O2" value="73.4" spread="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7" spread="18.5"/>
                    <measurement group_id="O2" value="85.2" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dryness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1" spread="23.8"/>
                    <measurement group_id="O2" value="73.5" spread="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.5" spread="17.6"/>
                    <measurement group_id="O2" value="86.6" spread="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vision</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.9" spread="19.7"/>
                    <measurement group_id="O2" value="82.0" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lens handling upon removal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.3" spread="15.5"/>
                    <measurement group_id="O2" value="86.6" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall impression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.8" spread="24.7"/>
                    <measurement group_id="O2" value="67.7" spread="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Acuity</title>
        <description>Visual acuity was assessed by distance high contrast logarithm of the minimum angle of resolution (logMAR).</description>
        <time_frame>1 month</time_frame>
        <population>There were 185 participants (370 eyes) in the redesigned group and 183 participants (366 eyes) in the control group who were eligible and dispensed lenses.</population>
        <group_list>
          <group group_id="O1">
            <title>Redesigned Purevision Contact Lens</title>
            <description>Redesigned Bausch &amp; Lomb PureVision contact lens&#xD;
Redesigned Purevision Contact Lens: Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.</description>
          </group>
          <group group_id="O2">
            <title>PureVision Contact Lens</title>
            <description>Bausch &amp; Lomb PureVision contact lens&#xD;
PureVision Contact Lens: Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity</title>
          <description>Visual acuity was assessed by distance high contrast logarithm of the minimum angle of resolution (logMAR).</description>
          <population>There were 185 participants (370 eyes) in the redesigned group and 183 participants (366 eyes) in the control group who were eligible and dispensed lenses.</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="370"/>
                <count group_id="O2" value="366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.028" spread="0.068"/>
                    <measurement group_id="O2" value="-0.021" spread="0.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Eyes With &gt; Grade 2 Slit Lamp Findings</title>
        <description>Graded slit lamp findings for each eye, including epithelial edema, epithelial microcysts, corneal staining, limbal and bulbar injections, upper lid tarsal conjunctival abnormalities, corneal neovascularization, and corneal infiltrates were graded for severity on a scale from 0 (No Finding) to 4 (Severe Finding). The outcome measure is any finding &gt; grade 2, across abnormalities.</description>
        <time_frame>1 month</time_frame>
        <population>There were 188 participants (376 eyes) enrolled into each group, for a total of 376 participants enrolled (752 eyes). There were 372 eyes in the redesigned group and 374 eyes in the control group assessed for slit lamp findings during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Redesigned Purevision Contact Lens</title>
            <description>Redesigned Bausch &amp; Lomb PureVision contact lens&#xD;
Redesigned Purevision Contact Lens: Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.</description>
          </group>
          <group group_id="O2">
            <title>PureVision Contact Lens</title>
            <description>Bausch &amp; Lomb PureVision contact lens&#xD;
PureVision Contact Lens: Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Eyes With &gt; Grade 2 Slit Lamp Findings</title>
          <description>Graded slit lamp findings for each eye, including epithelial edema, epithelial microcysts, corneal staining, limbal and bulbar injections, upper lid tarsal conjunctival abnormalities, corneal neovascularization, and corneal infiltrates were graded for severity on a scale from 0 (No Finding) to 4 (Severe Finding). The outcome measure is any finding &gt; grade 2, across abnormalities.</description>
          <population>There were 188 participants (376 eyes) enrolled into each group, for a total of 376 participants enrolled (752 eyes). There were 372 eyes in the redesigned group and 374 eyes in the control group assessed for slit lamp findings during the study.</population>
          <units>eyes</units>
          <param>Count of Units</param>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="187"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
                <count group_id="O2" value="374"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <desc>Adverse events were not coded. Therefore, source vocabulary is not applicable. There were 376 eyes dispensed the test lens and 376 eyes dispensed the control lens, assessed for adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Redesigned Purevision Contact Lens</title>
          <description>Redesigned Bausch &amp; Lomb PureVision contact lens&#xD;
Redesigned Purevision Contact Lens: Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.</description>
        </group>
        <group group_id="E2">
          <title>PureVision Contact Lens</title>
          <description>Bausch &amp; Lomb PureVision contact lens&#xD;
PureVision Contact Lens: Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Contact sponsor directly for details.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Bausch Health</organization>
      <phone>908-300-9920</phone>
      <email>susan.harris@bauschhealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

